Investors

Kadimastem on Tel-Aviv Stock Exchange

March 19, 2023 at 7:43:32 AM

February 19, 2023 at 10:13:44 AM

February 15, 2023 at 10:16:24 AM

February 5, 2023 at 8:15:19 AM

January 9, 2023 at 2:19:09 PM

December 20, 2022 at 9:55:35 AM

September 28, 2022 at 6:47:50 AM

August 9, 2022 at 7:36:45 AM

June 8, 2022 at 6:24:04 AM

May 30, 2022 at 12:56:40 PM

May 17, 2022 at 9:00:00 PM

March 3, 2022 at 1:08:29 PM

December 13, 2021 at 10:36:37 AM

November 29, 2021 at 12:20:17 PM

November 15, 2021 at 6:28:17 AM

October 26, 2021 at 5:52:59 AM

October 12, 2021 at 1:45:54 PM

July 21, 2021 at 12:46:30 PM

May 11, 2021 at 11:30:15 AM

April 26, 2021 at 7:19:04 AM

March 9, 2021 at 9:00:16 AM

January 31, 2021 at 10:59:20 AM

December 15, 2020 at 1:56:27 PM

August 3, 2020 at 7:11:53 AM

July 27, 2020 at 1:25:35 PM

July 27, 2020 at 1:25:54 PM

July 27, 2020 at 1:27:08 PM

July 27, 2020 at 1:28:11 PM

November 17, 2019 at 2:10:12 PM

July 27, 2020 at 1:30:03 PM

Investors

Investors

For More Investors Info.

Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS

Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS

Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine

Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening

Kadimastem Announces it raised appx 7.5 million NIS by rights offering

Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant

Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

ILEX Medical to Invest 10 million NIS ($3.2 million)

We rang the TASE bell today!

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement

Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan

Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article

Kadimastem Raises NIS 22.3 Million ($6.8 Million)

Kadimastem Granted a Patent in Israel for the Treatment of ALS

Kadimastem Announces Executive Management Changes

Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in

Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

Kadimastem Announces the Completion of Treatment for Cohort B

Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes

Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol

Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv

Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS